Its for investors who bought stock between April 29, 2025, and June 22, 2025 (the Class Period)
None is related to the work presented herein
You can indicate a treatment preference, but the final decision rests with the prescribing specialist based on your clinical profile
Dual incretin agonists achieve greater weight reduction than GLP-1RAs alone, and tirzepatide has now demonstrated cardiovascular safety noninferior to a proven GLP-1RA in patients with ASCVD as well as benefit in obesity-related HFpEF [40, 45]
From evolving consumer expectations and the importance of robust product testing, to new ingredient developments, biomaterials, and emerging biological approaches, the discussion offered valuable insight into the future of hair and scalp care
We also add MCT powder, which absorbs 4X more efficiently